Dermatology Practice Software: Is ModMed EMA Enough, or Do You Need a Layer Above It?

When is off the shelf genuinely the right call here?

Buy, and stop reading here, if you run one to three locations on a single electronic medical record, or EMR, with one pathology lab and either no cosmetic line or one under about 15 per cent of revenue. ModMed EMA is a strong product for that practice. Its body map is fine, its pathology module works when one clinical lead can hold the whole specimen pile in their head, and its per provider monthly price is far cheaper than anything you would build.

If that describes you and you are still frustrated, your problem is workflow discipline rather than software. We say this on calls and do not charge for it. A biopsy that nobody called about because the task list was shared across two front desks is not a product defect, it is an ownership defect, and a new system inherits it unless the ownership question is answered first.

Nextech is the better buy if your cosmetic line is significant but sits at a single location. Its cosmetic module is genuinely stronger on that side, and single site package logic never hits the ceiling that cross location redemption does.

Buy specialist tools rather than rebuilding them, too. Total body photography systems such as Canfield VECTRA do imaging properly. Aesthetic Record does what a single site cosmetic practice needs. The mistake is not buying any of these. It is expecting a product built for one practice to behave as a subordinate system inside a group.

When does a custom build actually pay off?

Four signals, and you will recognise them without a consultant.

You run more than one record system and no realistic plan to consolidate, because the migration quote came back worse than the pain. Your biopsy tracking lives in a spreadsheet that one named person owns, and you have quietly worried about what happens when that person leaves. Somebody spends five or more hours a week producing a revenue report by hand that is four days stale by the time it lands. Or you are acquiring two practices a year.

That last one decides it. Every practice you buy arrives with its own record instance, its own templates and its own way of coding a skin check. Integration debt compounds annually, and the buyer who eventually asks for group level operational data will not accept that you cannot produce it.

The clinical case is sharper than the commercial one. Every derm record system models a specimen going out, a result coming in and a provider signing it. None models the obligation a positive result creates. Nothing in the software knows that a basal cell carcinoma on the nose of a 71 year old means call within 48 hours, schedule surgery within 30 days, and if the patient does not answer, try twice more and then send a letter. Before you commission anything, reconcile your own biopsy log against your records and count how many positive results sat past 14 days without documented patient contact. Every group we have run that query for has found the number uncomfortable, and that number is the actual business case.

How do they compare on the things that matter in this industry?

• The lesion as an object. Record systems are encounter centric because billing is encounter centric. There is no persistent identifier for the mole on a patient's left scapula, so nothing for a photo, a measurement, a biopsy or a diagnosis to attach to over four years. That is a data model consequence, not carelessness, and no configuration reaches it.
• Obligations with clocks. A pathology module tracks a document. What closes a loop is a state machine where each transition carries a service level that varies by diagnosis, so a melanoma escalates to the medical director on breach and a benign nevus closes itself.
• Narrative pathology reports. A national lab with a structured interface is a known quantity. A regional dermatopathology lab that faxes narrative PDFs needs classification and extraction for diagnosis, margin status, depth and site correlation, plus a queue for cases where the report site and the requisition site disagree.
• Patient identity across systems. Your cosmetic system and your record system do not share a patient key, and the cosmetic product will never join to your medical data because it was not designed to be subordinate. Resolution on name, date of birth, phone and email with a human review queue is the precondition for every cosmetic revenue question you want answered.
• Cross site comparability. Record reporting slices by provider and location but not by visit complexity, and acquired sites on a second system are not in the report at all. Normalising nightly extracts into one schema is what makes Westside and Northgate comparable.
• Booking rules. A full body check with a melanoma history needs 30 minutes with a physician, not a physician assistant. Generic schedulers do not encode that, so your front desk encodes it as tribal knowledge that leaves with turnover.

What does total cost of ownership look like at your scale?

From Digital Heroes delivery experience, a focused first release runs $60,000 to $130,000 and ships in 12 to 16 weeks. For dermatology that is almost always the biopsy to closure tracker with pathology extraction, because it carries the clearest risk story and it forces you to solve patient identity resolution and record integration early, which everything else depends on. A full platform adding the lesion timeline, the unified medical and cosmetic ledger, triage booking and the group dashboard runs $150,000 to $400,000 phased over 6 to 12 months.

A worked shape: a nine location group running ModMed EMA at seven sites and Nextech at two acquired practices, with one structured pathology lab and one PDF lab, scoped to biopsy closure across every site, lands near $125,000. Consolidating onto one record system first removes about $16,000 of that. Sending all pathology to one structured lab removes about $8,000 more.

Phase pricing after that is predictable. The lesion timeline with photo capture is $45,000 to $95,000 over 10 to 14 weeks. The cosmetic ledger and triage booking is $60,000 to $140,000 over 12 to 18 weeks, with your package rules setting the range: simple prepaid session counts at the bottom, memberships with per injector attribution and cross location redemption at the top.

Running cost is 15 to 20 per cent of build cost annually, so $19,000 to $25,000 on the $125,000 example. Image storage grows on its own because dermatology data is imaging heavy and retention is long. Pathology adapters need an owner and a test corpus of real historical reports, since labs change formats when they upgrade and do not consult you first.

The comparison is unusual because you are not cancelling anything. You keep paying ModMed or Nextech, so the return has to come from labour and risk rather than substitution. Two staff spending a combined ten hours a week on reports and a biopsy log is typically $30,000 to $50,000 a year of salary producing stale information.

What does the hybrid look like, and when is it the honest answer?

In dermatology the hybrid is the only answer we recommend. Keep the record system, build the layer above it.

Do not replace the EMR. Billing lives there, your payers are integrated with it, and rebuilding one is a seven figure mistake we have watched groups make. The layer reads nightly from every record instance, normalises into one schema where a visit is a visit and a biopsy is a biopsy regardless of source, and writes structured notes back so your billing and legal record stay where compliance expects them.

The same discipline applies sideways. Keep Aesthetic Record if a site uses it. Keep your total body photography unit. Buy the pathology interfaces the national labs already publish. What you build is the joins: the lesion entity, the specimen state machine, the identity resolution layer and the unified ledger. Those exist in the gaps between products, which is exactly why no vendor will ever ship them.

Sequencing matters. One problem finished across every site beats three problems half finished at two sites. The biopsy tracker at nine locations removes group wide risk and produces the integration work everything else reuses. Lesion timeline second. Cosmetic ledger third, once identity resolution is already paid for by the first release.

Two smaller decisions hold cost down without reducing value. Leave photographs where they are in phase one and link to them rather than migrating terabytes. And freeze your cosmetic package rules before the build instead of rationalising them during it, because rationalising pricing mid build arrives as an engineering change order.

Which should you choose, by operator size and stage?

One to three locations, one record system, one lab, small cosmetic line: buy. ModMed EMA, configured properly, with one named owner for the biopsy pile. Nothing else on this page applies yet.

Four to six locations on one record system: buy, and measure. Time how long the weekly revenue report takes and count how many positive biopsies are currently past 14 days without documented contact. Those two numbers, not location count, tell you whether you have crossed. If the second number is anything other than zero, fix ownership before you fix software.

Six or more locations, or above roughly 40,000 annual visits: build the first release. The biopsy tracker across every site, with identity resolution and record integration underneath. Expect 12 to 16 weeks, and budget a week of clinical staff time before go live to work the backlog the new system surfaces on day one.

Any group running two or more record systems: build, whatever your location count. This is the case products cannot serve, because normalisation only exists once two sources disagree and no vendor has any reason to integrate deeply with a competitor.

Groups acquiring two or more practices a year: build now rather than later. Each additional record system is roughly $12,000 to $18,000 of integration, and the third is much cheaper than the second because the normalisation layer already exists. Building after five acquisitions costs more and produces a worse history than building after two.

Groups where cosmetic is above a quarter of revenue across several sites: build the ledger even at modest location counts. Package liability, cosmetic attach rate from medical visits and per injector retention are questions your current stack cannot answer at any price, because the two systems do not share a patient.

If you would rather scope this before committing budget, Digital Heroes has delivered more than 2,000 projects with a named team you can speak to before you sign, rather than a bench you meet in month two. The document is yours whichever way you go.